The unique characteristics of MET exon 14 mutation in Chinese non-small cell lung cancer patients
Si-Yang Liu,Lan-Ying Gou,Xu-Chao Zhang,Wen-Zhao Zhong
2016-01-01
Abstract:IntroductionPredictive biomarkers of MET-targeted t herapy remain elusive (mesenchymalto-epithelial transition, MET). Since the discovery of the MET exon 14 mutation, it has been found to have the best potential to become one prec ise biomarker for MET-targeted therapy. Here, we present the unique characteristics of MET exon 14 mutations in Chinese patients with non-small cell lung cancer (NSCLC). Methods M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 2 A total of 1,296 patients with NSCLC were screened for MET exon 14 mutations. Nextgeneration sequencing was performed on the DNA of 9 68 patients and Sanger sequencing was conducted on cDNA of the other 328 patients. Im munohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) were also performed on all sp ecimens. Results Twelve patients had MET exon 14 mutations. These accounted for only 0.9% o f adenocarcinoma. Thus the mutations were present at less han half the frequency of occurrence in Western patients (Chinese vs. Caucasi ans: 0.9% vs. 3%, χ=15.1, p < 0.001). Samples from six patients with MET exon 14 mutations were analyzed using IHC and FISH. We found no significant relatio nships among the mutation, MET amplification, and MET overexpression. In two patie n s who received crizotinib, only one patient (who exhibited MET amplification) experienced a partial response; the progressionfree survival was 9 months. However, it remains unc lear whether the sensitivity of this patient to crizotinib was conferred by the MET exon 14 mutation per se, or by MET amplification. In the other patient with concomitan t MET exon 14 skipping and KRAS G12D mutation, the disease progressed in only 1 month. Conclusion MET exon 14 mutation per se may not be sufficiently ro bust for use in defining a subset of NSCLCs. Further research on MET exon 14 mutations, MET amplification, and MET overexpression is required. Maybe a panel of biomar kers will be necessary in the future. M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 3 Introduction The discovery of targetable genomic alterations has brought the treatment of non-small cell lung cancer (NSCLC) into the era of precision medicine. Since then a ne w term, “driver gene,” has entered the sight of clinical oncologist s, and the novel associated concept encourages the development of more effective target ed therapies for certain subsets of lung cancer patients. The median overall survival (OS) h as been prolonged to 3.5 years in patients whose tumors harbor driver genes , including EGFR, ALK and ROS1. Moreover, MET has been identified as a novel promising target. It has been suggested that either an METactivating mutation or genomic amplification of MET plays a role in lung cancer. However, unlike work with EGFR or ALK, clinical studies on MET-targeting cancer therapeutics have yielded mixed outcomes. The utili ty of MET as a lung cancer target once seemed in doubt. The newly defined cutoff point for MET amplification (an MET/CEP7 ratio ≥5) has begun to dispel this pessimism . Last year the discovery of MET exon 14 mutations further focused attention on MET-targeting therapies . In fact, MET exon 14 skipping was first recognized in NSCLC patients over 10 years ag o. Loss of exon 14 leads directly to deletion of the intracellular MET juxtamembrane dom ain, which contains critical regulatory elements that promote MET protein degradation. Thes e include tyrosine 1003, the binding site for Cbl (an E3 ubiquitin ligase). As a result, MET exon 14 mutation prolongs MET signaling and increases the oncogenic potential. In 2015, two important papers reported gratifyingly that almost 3% of patients with lung adenocarcinomas harbored an MET exon 14 mutation and responded effectively to MET inhibitors such as crizotinib. Very recently, Awad et al. reported results consistent with the earlier findings. Furthermore, the clinical charact eristics of patients harboring MET exon 14 mutations were described in detail . Thus, MET exon 14 mutations have become a novel target for precision therapy of NSCLC. However, East Asian patients with lung cancer have their own molecular characteristics that differ from those of Caucasians, in particular in terms of EGFR and KRAS status. Thus, to explore the clinical features of Chinese patient s wi h the novel MET target, we sought MET mutations in patients at our institution and attemp ted to treat those with these mutations with crizotinib. We hoped that MET exon 14 mutation status would define a subset of l ung cancer patients for whom we could optimize genotype-direct ed therapies. However just like “life is just a rugged mountain r oad and you would never know what would be next around the corner”, when we reviewed our screening data and attempted to M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 4 summarize the clinical features of Chinese patients , we came to conclusions different from Western studies. Materials and Methods Study Population Our study population was composed of patients treat ed between January 1 2013 and November 1 2015. Tumor biopsies were obtained using a protocol approved by our Institutional Review Board. All patients provided w ritten informed consent. Next-Generation Sequencing We profiled DNA from all tissue samples using a cap ture-based targeted sequencing panel. Human genomic regions totaling 2.02 MB in si ze, ncluding selected exons and introns of 295 genes, were captured using 120bp probes. DNA was fragmented into segments 200– 250bp in length, captured by the120 bp probes, and sequenced by obtaining paired 2×150bp reads. After DNA extraction (QIAamp DNA FFPE tissue kit), DNA concentrations were measured using the Qubit dsDNA assay. The DNA quali ty was confirmed by checking that the A260/A280 ratio was 1.8–2.0. DNA was hybridized with the capture probes (the baits), selected using magnetic beads, and PCR-amplified. T hen a bioanalyzer (Qubit and Agilent 2100) was used to perform high-sensitivity assays a ssessing DNA quality and size range. All samples were sequenced on a NextSeq 500 platform (I llu ina, Inc., USA); we obtained pairend reads. For tissue samples, we aimed to achieve an average sequencing depth of 1,000× for all targeted regions.